Singapore markets close in 1 hour 37 minutes

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
6.26+0.19 (+3.13%)
At close: 04:00PM EST
6.23 -0.03 (-0.48%)
After hours: 07:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous close6.07
Bid0.00 x 2900
Ask0.00 x 3200
Day's range5.76 - 6.28
52-week range3.21 - 9.36
Avg. volume7,287,349
Market cap1.602B
Beta (5Y monthly)0.11
PE ratio (TTM)N/A
EPS (TTM)-2.08
Earnings date26 Feb 2024 - 01 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est20.42
  • Motley Fool

    Why Iovance Biotherapeutics Stock Is Jumping Today

    Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were jumping 10.9% higher as of 11:49 a.m. ET on Monday. The nice gain came after Goldman Sachs initiated coverage on Iovance stock with a buy recommendation. Investors no doubt liked Goldman Sachs' 12-month price target of $12 for Iovance.

  • GlobeNewswire

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that on November 16, 2023 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 59,950 shares of Iovance’s common stock to nine new non-executive employees. The awards

  • Insider Monkey

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript

    Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2023 Earnings Call Transcript November 7, 2023 Iovance Biotherapeutics, Inc. reports earnings inline with expectations. Reported EPS is $-0.46 EPS, expectations were $-0.46. Operator: Welcome to the Iovance Biotherapeutics Third Quarter and Year-to-Date 2023 Financial Results and Corporate Update Conference Call. My name is Abigail, and I will be your […]